The PERSIST-1 trial for pacritinib is expected by the company to enroll 270 patients. Myelofibrosis patients in pacritinib's phase 2 trial showed clinical benefits and tolerated the drug well, according to Cell Therapeutics, making the PERSIST-1 trial a key step up for the drug's progress.
Myelofibrosis is estimated to afflict around 30,000 individuals in the United States. The disease, a chronic bone marrow disorder, can cause an enlarged spleen, anemia, and extreme fatigue, among other symptoms.
Company Chief Medical Officer Dr. Steven E. Benner talked about the trial in a company press release, saying, "Data from earlier studies of pacritinib showed a clinically meaningful improvement in symptoms without suppression of platelets or red blood cells. We believe that pacritinib has the potential to offer an effective and well-tolerated treatment option for myelofibrosis patients, and are pleased to be initiating the Phase 3 PERSIST-1 clinical trial."
Dan Carroll has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.